Loading
Life sciences · Journal article
Journal of Nanobiotechnology · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Sepsis, a severe illness marked by immune dysregulation and widespread inflammation, involves macrophage pyroptosis as a key player. This study explores the impact of RNA N6-methyladenosine (m 6 A) modification and investigates whether fat mass and obesity-associated protein (FTO)-mediated demethylation influences macrophage pyroptosis by modulating NOD-like receptor protein 3 (NLRP3) inflammasome activation. The research aims to unravel the workings of the FTO-m 6 A-NLRP3 pathway in macrophage pyroptosis and assess the therapeutic potential of targeted intervention using biomimetic nanovesicles. Results:By developing CD11b/CD206 dual-ligand modified macrophage-derived small extracellular vesicle (sEV)-biomimetic nanovesicles loaded with FB23-2, an FTO inhibitor (FB23-2-loaded Dual-Vesicles) and employing various molecular techniques, including MeRIP-qPCR, WB, scRNA-seq, spatial transcriptomics, and metabolomics, the study delves into the mechanism by which FTO-regulated m 6 A modification impacts NLRP3 inflammasome and inflammatory metabolic pathways. Findings reveal upregulated FTO levels in septic macrophages, reduced m 6 A modification levels, and increased expression of NLRP3 and interleukin-1 beta (IL-1β). Treatment with an FTO inhibitor increased m6A modification of Il1b mRNA, reduced IL-1β expression, and attenuated NLRP3 inflammasome activation and pyroptosis-associated changes. FB23-2-loaded Dual-Vesicles showed enhanced macrophage uptake and pulmonary enrichment, improved 7-day survival, and reduced inflammatory injury in murine models. Conclusions: These findings support further evaluation of the FTO-m6A-NLRP3-pyroptosis regulatory network as a targeted epigenetic intervention strategy in sepsis and related inflammatory diseases.